Abstract:Conventional detection methods cannot fully reflect the overall landscape of tumor, which misguide the use of targeted drugs and lead to poor prognosis. Here, based on the results of genomic profiling obtained by NGS, we interrogate the underlying mechanism of differential response to EGFR-TKI in EGFR-positive patients with lung cancer. 207 patients with advanced non-small cell lung cancer (NSCLC) carrying EGFR_L858 or 19del (identified by conventional methods) from 7 clinical trials (such as FLAURA, CTONG1405 and CTONG1509) were enrolled. 457 plasma (n=335) or tissue (n=122) samples from baseline and follow-up points of the cohort were profiled using 168-/520-cancer-related gene panels. Molecular characteristics in patients with rapid progression (PFS<3 months, n=10) and durable response (PFS>24 months, n=6) to EGFR-TKI treatment were analyzed. The accuracy of NGS and conventional methods for identifying EGFR driver mutations in tissue samples was 97.1%, and that of driver mutation detection in plasma and tissue samples was 81.9%. Using NGS, several alterations at baseline that may potentially affect prognosis were identified, in addition to EGFR oncogenic mutations revealed by traditional methods. Ten patients progressed rapidly on EGFR-TKI therapy (no response, n=4; stable disease, SD, n=2; partial response, PR, n=4). Of the 4 patients who did not respond to EGFR-TKI, ALK fusion, NTRK fusion, MET amplification (METamp) and EGFR_E709A were identified at baseline using NGS. Of the 2 patients received SD, NGS revealed that one case carried mutations in TP53, PMS2, PALB2 and ARID1A, while another case carried TP53_R213* and ERBB2amp. As to the 4 patients achieved PR, NGS results showed that one patient carried TP53_R342* and EGFR_L62R; one patient with CDK4amp and RET pathogenic mutation; one patient had TP53_V216L, CDK4amp, ERBB2amp and EGFRamp; and another patient harbored CDK4amp. In contrast, of the 6 patients achieved durable response to EGFR-TKI, NGS revealed that 4 patients did not carry any alteration or well-established factor associated with poor prognosis other than EGFR driver mutations. The other 2 patients with TP53 mutation and EGFRamp received combination treatment of EGFR TKI and chemotherapy. NGS had good consistency with conventional methods in identifying EGFR-driver mutation. Compared with traditional methods, NGS can represent more comprehensive landscape of tumor and provide more reliable guidance for treatment. For patients with EGFR-driver mutations along with tumor suppressor or oncogene mutations, combination therapy of TKI and chemotherapy might be a better option than TKI alone. In addition, we revealed that EGFR_E709A and EGFR_L62R may be potential resistance mechanisms of EGFR TKI.

Concurrent Driver Gene Mutations As Negative Predictive Factors in EGFR Positive Non-Small Cell Lung Cancer

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

P1.01-92 Underlying Mechanisms That Potentially Affect Prognosis to EGFR-TKI in EGFR-Positive Patients with Non-Small Cell Lung Cancer

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations.

Clinical Features and Therapeutic Options in Non‐small Cell Lung Cancer Patients with Concomitant Mutations of EGFR, ALK, ROS1, KRAS or BRAF

The Impact of EGFR Exon 19 Deletion Subtypes on Clinical Outcomes in Non-Small Cell Lung Cancer

Different Stories for Different EGFR Exon 19 Deletion Variants

Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations

Uncommon EGFR Mutations in a Cohort of Chinese NSCLC Patients and Outcomes of First-Line EGFR-TKIs and Platinum-Based Chemotherapy.

EGFR Tyrosine Kinase Inhibitor (TKI) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Uncommon EGFR Mutations: A Real-World Study in China.

Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma

[The Concomitant Gene Alterations Impact the Therapeutic Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Sensitive Mutation].

Concurrent Gene Alterations with EGFR Mutation and Treatment Efficacy of EGFR-TKIs in Chinese Patients with Non-Small Cell Lung Cancer

P1.01-035 A Next Generation Sequencing and Characteristics Based Model for Predict Clinical Benefits of Advanced NSCLC Patients

The Predictive Role of Pretreatment Epidermal Growth Factor Receptor T790M Mutation on the Progression-Free Survival of Tyrosine-Kinase Inhibitor-Treated Non-Small Cell Lung Cancer Patients: a Meta-Analysis

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR -Activating Mutation In Non- Small Cell Lung Cancer

P2.01-117 Concurrent Gene Alterations in Treatment-Naïve EGFR-Mutant Advanced Non-Small Cell Lung Cancer

Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations

Comprehensive Investigation of Oncogenic Driver Mutations in Chinese Non-Small Cell Lung Cancer Patients.

Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer

Clinical Outcomes of EGFR-TKI Treatment and Genetic Heterogeneity in Lung Adenocarcinoma Patients with EGFR Mutations on Exons 19 and 21